The Medical Briefing Nephrology
Calcitriol in IgA nephropathy, “universal” kidney, CONFIDENCE, FIDELITY
Retrospective no. 11/12
The essentials in four articles
■ Glomerular disease
138 patients with IgA nephropathy and proteinuria > 0.5 g/day: oral calcitriol 0.25 µg/day added to RAS blockade for 12 months, UPCR −187 mg/g vs placebo, annual GFR decline −0.32 vs −3.64 mL/min/year, with no excess hypercalcemia.
■ Transplantation
Ex vivo perfusion of enzymes converts a group A kidney into a “universal” group O kidney (ECO-kidney); in a brain-dead recipient with a high anti-A antibody titer, no hyperacute rejection was observed.
■ CKD and dialysis
800 patients with CKD and type 2 diabetes: UACR −52% with finerenone + empagliflozin dual therapy, with an additional reduction of 32% versus empagliflozin alone and 29% versus finerenone alone.
■ CKD and dialysis
Pooled analysis of FIDELIO-DKD and FIGARO-DKD (12,990 patients): the kidney benefit of finerenone on GFR decline is seen across degrees of frailty, with a more marked absolute benefit in frail patients.